U.S. orphan drug status granted to decitabine plus tetrahydrouridine for thalassemia Feb. 21, 2017 No Comments
Modus Therapeutics completes financing to support phase II trial of sevuparin Feb. 20, 2017 No Comments
FDA advisory committee meeting not needed for Portola Pharmaceuticals' betrixaban NDA Feb. 9, 2017 No Comments
Promising MOD-5014 results in a phase I/IIa clinical trial in hemophilia patients Feb. 3, 2017 No Comments
RSS